While its true that some individuals experience weight regain after coming off GLP-1 therapy, its not inevitable
These are often described as either purging or breakouts, but they are not the same
Hypoglycemia: The risk is less with GLP-1 RAs
"The risk of developing these severe side effects is very small, but it is important that patients and healthcare professionals are aware and alert to the associated symptoms." In the UK, the most commonly used GLP-1 therapies are Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity, as well as Eli Lilly's Mounjaro (tirzepatide), which are all given as weekly injections
It's really just sticky, inflamed endothelium that draws the cholesterol to try to heal the process
Portion control Because semaglutide helps slow gastric emptying, or the rate your stomach empties after eating, many people find it naturally encourages smaller portion sizes